The active ingredient, Trimetazidine, is considered relevant for the symptomatic management of adult patients with stable angina pectoris. This is relevant in conditions characterized by periods of heightened symptoms, specifically the recurrent chest discomfort or pressure associated with angina.

The medication plays a role in managing symptom clusters that may become intense or disruptive, helping to address both the frequency of these episodes and the limitations on physical capacity they impose. It is often applied during phases when symptoms become more noticeable, particularly when the patient requires additional symptomatic assistance beyond standard antianginal agents.

Quick Fact: Relief for Recurrent Chest Discomfort

The use of this medicine is considered relevant for assisting with functional stability, and it may help ease symptoms that are triggered by physical activity. This supports patients during difficult episodes, contributing to improved comfort during symptomatic periods. Its use may also contribute to easing the reliance on short-acting rescue medication.

“This medicine is commonly used to help with limitations on exertion, assisting patients with managing the physiological strain of chronic stable heart conditions.”

Regulatory References

1. European Medicines Agency

Official Population Eligibility for Vastarel 35 mg

The eligibility for using Vastarel 35 mg (Trimetazidine) is strictly defined by regulatory documentation and is based on age, existing health conditions, and organ function. The medication is only approved for use in adults for the symptomatic treatment of stable angina pectoris.

Absolute Contraindications (Must Not Use)

Population Group	Condition	Regulatory Status
Neurological	Parkinson disease, parkinsonian symptoms, tremors, or restless leg syndrome	Contraindicated
Renal Function	Severe renal impairment (Creatinine clearance less than 30 mL/min)	Contraindicated
All Patients	Hypersensitivity to Trimetazidine or any excipients	Contraindicated

Restricted or Non-Recommended Use

Use is not established and is not recommended for the pediatric population (children and adolescents under 18 years of age).

Older adults (those over 75 years) and patients with moderate renal impairment (Creatinine clearance 30–60 mL/min) are restricted-use populations, which requires specific regulatory caution. For maternal health, the medicine is not recommended during either pregnancy or breastfeeding as a precautionary measure due to insufficient data.

The official regulatory profile for Trimetazidine indicates that no specific drug-drug interactions have been formally reported or identified that would necessitate the prohibition of co-administration with other medicines. This is supported by studies that found Trimetazidine is neither an inhibitor nor an inducer of key drug-metabolizing enzymes and does not significantly alter the pharmacokinetics of tested medicines such as digoxin or theophylline.

Documented Interaction Patterns

While no pharmacokinetic drug-drug interactions are documented, there is a pharmacodynamic caution regarding co-administration with other treatments:

• Antihypertensive Treatments: Official labeling notes an increased risk of hypotension and falls when Trimetazidine is taken concurrently with any antihypertensive treatments. This is due to a potential additive effect on blood pressure and gait stability.

Exposure and Clearance Considerations

The regulatory profile identifies specific population groups where the medicine’s exposure is expected to be altered, a factor derived from pharmacokinetic analysis:

• Moderate Renal Impairment: Increased plasma concentrations (exposure) of Trimetazidine are expected in patients with moderate renal impairment (creatinine clearance between 30 and 60 mL/min).
• Elderly Patients: Increased exposure is also expected in elderly patients aged 75 years and older due to age-related decline in renal function.

Official documents confirm the medicine’s pharmacokinetic characteristics are not influenced by co-administration with meals, and they do not mandate a specific timing separation between Trimetazidine and other medicinal products.

Trimetazidine, the active ingredient in Vastarel 35 mg, is a metabolic agent that exerts its effects by modulating how heart muscle cells ( cardiomyocytes) produce energy, contributing to the maintenance of cellular integrity during low oxygen conditions (ischemia). The mechanism operates independently of heart rate or blood pressure changes.

Trimetazidine selectively inhibits the mitochondrial enzyme Long-Chain 3-Ketoacyl Coenzyme A Thiolase ( 3-KAT), which is essential for fatty acid breakdown ( oxidation). This enzymatic blockade alters the heart's energy substrate usage, initiating a metabolic cascade where the cell switches its primary fuel source from fatty acids to glucose oxidation ( glycolysis).

Since the glucose pathway requires less oxygen to generate the same amount of ATP (energy), this shift results in an increased overall oxygen efficiency of the heart muscle. This physiological effect maintains intracellular balance in the cardiomyocyte by supporting the function of critical ion pumps, limiting calcium overload, and reducing the accumulation of acidic byproducts. This action supports the maintenance of contractile force and cellular structure during low oxygen states.

Official Administration Guidelines

This section describes the usage instructions for the 35 mg Modified-Release tablet.

Administration Scope	Official Instructions
Route of Administration	Oral administration (by mouth).
Standard Dosing Schedule	One 35 mg tablet is taken twice daily, resulting in a total daily dose of 70 mg of Trimetazidine.
Timing in Relation to Meals	Must be taken during meals, specifically one dose in the morning and one in the evening.
Preparation Requirements	The Modified-Release tablet must be swallowed whole with water and must not be crushed, chewed, or divided.

Population-Specific Dosing Rules

Special Population	Adjustment/Rule
Moderate Renal Impairment	The recommended dose is reduced to one 35 mg tablet taken only once daily, typically in the morning with breakfast.
Elderly Patients	Caution and close monitoring are advised, especially in patients over 75 years old or those with moderate renal impairment, where the dose reduction rule applies.
Paediatric Population	Use is not recommended, as the safety and efficacy have not been established in patients under 18 years of age.

Official Procedural Conditions

If a dose is missed, the patient should resume treatment with the next dose at the usual scheduled time and must not take a double dose to compensate for the missed one. The continuation of the treatment must be formally assessed after a three-month course, and the medication should be discontinued if no satisfactory response is observed.

These instructions establish the required oral route and the fixed twice-daily frequency for standard use of the 35 mg Modified-Release tablet. The protocol specifies intake with meals and defines mandatory dose adjustments based on renal function.

Recent Clinical Evidence

Vastarel 35 mg (Trimetazidine modified release) is an anti-ischemic agent that has been studied primarily as an add-on therapy for the symptomatic management of stable angina pectoris. Clinical research has aimed to assess its effects on heart function, symptoms, and exercise capacity in patients who have not been fully controlled by first-line anti-anginal medications.

---

Impact on Symptoms and Exercise Capacity

Meta-analyses of randomized, double-blind controlled trials have evaluated Trimetazidine's use in patients with stable angina.

• Angina Frequency: Studies suggest that when used in addition to conventional treatment, the addition of Trimetazidine was associated with a reduction in the number of weekly angina attacks reported by participants.
• Nitrate Use: Research also indicated a decrease in the frequency of short-acting nitrate (nitroglycerin) use per week, suggesting an improvement in symptom control.
• Exercise Tolerance: In several trials, the drug's use was linked to an increase in total exercise duration and an increase in the time taken to develop signs of exercise-induced ischemia (ST-segment depression) during treadmill testing.

---

Advanced Cardiovascular Research

More recent trials have explored the use of Trimetazidine in specific cardiovascular contexts, such as patients who have recently undergone Percutaneous Coronary Intervention (PCI). The large-scale ATPCI trial did not show a difference between Trimetazidine and placebo groups for reducing major adverse cardiac events (MACE) over a long follow-up period in this patient population.

However, other observational studies have described the drug's use alongside standard care in stable angina patients with persistent symptoms. Findings from these real-world studies generally indicated improvements in patient-reported physical activity and adherence to anti-anginal regimens.

Key Studies & References

1. The Trimetazidine in Patients with Angina post-PCI (ATPCI) Trial: Primary Results

Common questions about Vastarel 35 mg (FAQ)

---

Q: Is Vastarel 35 mg suitable for elderly patients?

Official product information notes that older patients may experience increased exposure to the medicine, mainly due to age-related changes in kidney function. Regulatory guidelines advise caution and close monitoring for those over 75 years old. If moderate kidney impairment is determined, a reduced dose may be necessary.

---

Q: Is it important to take Vastarel 35 mg at the same time every day?

The modified-release tablet is prescribed to be taken twice daily, once in the morning and once in the evening, with meals. Following a regular timing routine helps support this consistent exposure, as the formulation is designed to maintain a stable therapeutic concentration over a prolonged period.

---

Q: What is the purpose of the 35 mg dose?

The 35 mg unit is the specific strength chosen for the modified-release tablet formulation. This dose is prescribed for twice-daily administration, resulting in a total daily amount studied in clinical trials. This amount serves as the basis for the medicine's established effect on managing symptoms in stable angina.

---

Q: What is the likelihood of experiencing a serious side effect with Vastarel 35 mg?

Regulatory reviews indicate that serious adverse reactions, such as the development of Parkinsonian symptoms, have a low reported incidence in observational data. This risk is factored into the safety profile. If these specific movement disorders occur, they are usually noted to be reversible after the medication is stopped.

---

Q: How do regulatory agencies view the safety profile of Vastarel 35 mg?

The medicine's safety profile has undergone extensive regulatory review. A central finding is that for the intended use in stable angina, the benefits are considered to outweigh the known risks. This assessment has resulted in the introduction of specific warnings and new contraindications to appropriately manage possible risks, such as those related to movement disorders.

---

Q: Is Vastarel 35 mg used for long-term heart condition management?

Studies and official information indicate that the medicine may be used as a component of the long-term management strategy for stable angina pectoris. Treatment may be initiated and its benefit is formally assessed after a three-month period.

---

Q: How is Vastarel 35 mg different from other cardiovascular-related drugs?

The medicine is classified as a metabolic agent, meaning it affects the heart cell's energy process rather than its blood flow dynamics. The mechanism of action is described as operating by modulating the heart cell’s energy process rather than affecting blood flow. Official documents state that the drug does not significantly affect heart rate or blood pressure.

---

Q: How quickly can someone expect Vastarel 35 mg to start working?

The time it takes for the medicine to achieve its effects is related to its blood concentration. After the first dose, the maximum concentration of the active substance is typically achieved after about five hours. Consistent therapeutic levels, known as steady state, are generally reached after approximately 60 hours of continuous treatment.

---

Q: Is Vastarel 35 mg a drug that can cause withdrawal symptoms if stopped suddenly?

Regulatory information primarily addresses the reversibility of certain side effects upon discontinuation. Specifically, if the medicine is stopped due to the emergence of movement disorders, such as Parkinsonian symptoms, these effects are usually noted to be reversible after discontinuation.

---

Q: What should be done if a potential drug interaction is suspected?

Regulatory safety information advises patients to seek guidance if they notice any unusual effects. If you experience new side effects or suspect a potential drug interaction may be occurring, official safety information recommends consulting a doctor, pharmacist, or nurse.

---

Q: Are there warnings about driving or operating machinery while on Vastarel 35 mg?

Official product information contains specific warnings regarding tasks that require alertness. Because cases of dizziness and drowsiness have been observed during use, these observations indicate a potential impact on the ability to drive or operate machinery.

---

Q: Does Vastarel 35 mg have any known effect on blood sugar levels?

The medicine operates by modulating cellular energy processes. However, official safety data and side effect lists do not include changes in blood sugar levels as a reported adverse reaction.

---

Q: Are there specific instructions if Vastarel 35 mg is accidentally taken too much?

Regulatory documents provide clear procedural guidance for potential accidental misuse. If more of the medicine is taken than should be, official instructions recommend consulting a doctor or pharmacist immediately.

---

Q: What research is available on Vastarel 35 mg use in diabetic patients?

Clinical studies have examined the medicine's use in stable angina patients who also have Type 2 diabetes or diabetic cardiomyopathy. This research evaluates the drug’s effects on heart function within these specific patient populations.

---

Q: What are the official recommendations if a person experiences an allergic reaction to Vastarel 35 mg?

The official guidance addresses the risk of hypersensitivity and notes the medicine is contraindicated if a person is allergic to the active ingredient. Recommendations for a serious reaction, such as severe skin reactions, are to withdraw the drug immediately and official guidance recommends consulting a medical professional.

Storage and Disposal Requirements

The storage and disposal of Vastarel 35 mg (Trimetazidine dihydrochloride) must strictly follow the conditions defined in official regulatory documentation.

Storage Conditions

Requirement	Official Instruction
Temperature	Store at temperatures not exceeding 30 C (or below 25 C in some regions).
Stability	Do not use the tablets after the expiry date shown on the carton.
Child Safety	Keep out of the reach and sight of children.

Disposal Instructions

For disposal, the medicine should not be discarded via wastewater or standard household waste. Any unused or expired tablets must be handled and disposed of according to local regulatory requirements for pharmaceutical waste.